Clinical trials: Diabetes Type I
Type 1 Diabetes
Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study
The purpose of this study is to investigate the effect of using FreeStyle InsuLinx (a blood glucose meter with a built-in insulin calculator) on glucose control in people with type 1 diabetes.
- Trial name
- NCT01519466
- Testing
- FreeStyle InsuLinx, FreeStyle Freedom Lite
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 55 people
- Sponsor
- Abbott Diabetes Care
Type 1 Diabetes
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
- Trial name
- NCT05791201
- Testing
- VX-264
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 7 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetic (the rate at which the body eliminates the trial drug) and pharmacodynamic (the effect of the trial drug on the body) profiles of…
- Trial name
- NCT01296438
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus
The purpose of this study to assess the safety and tolerability of re-dosing at 6 months with otelixizumab (given as an 8-day series of intravenous infusions) in adult subjects with newly diagnosed type 1 diabetes mellitus
- Trial name
- NCT01222078
- Testing
- otelixizumab
- Where
- 2 sites in France, Germany
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus
This study will compare LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs will be given by injection under the skin of the abdomen.
- Trial name
- NCT03407118
- Testing
- LY900014, Insulin Lispro
- Where
- Japan
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
AT247, NovoRapid® and Fiasp® in Glucose Clamp Study
A Phase I, randomised, single-centre, double-blind, single-dose, three period, balanced cross over study in a glucose clamp setting.
- Trial name
- NCT03959514
- Testing
- NovoRapid, Fiasp, AT247
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Arecor Limited
Hypoglycemia
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of…
- Trial name
- NCT02081014
- Testing
- G-Pen Mini™ (glucagon injection)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes Mellitus, Type 1
Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions
The study is an open-label, randomized, two-period crossover study. Up to one hundred and twenty (120) subjects with type 1 diabetes mellitus (T1DM) who use the MiniMed paradigm insulin pump, who meet the inclusion/exclusion…
- Trial name
- Daily Life (NCT01283425)
- Testing
- InsuPatch
- Where
- 8 sites in United States, Israel
- Volunteers
- 147 people
- Sponsor
- Insuline Medical Ltd.
Diabetes, Diabetes Mellitus, Type 1
Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin
This trial is conducted in Europe. This is a single-centre, retrospective trial aiming at comparing the antibody levels in children and adolescents.
- Trial name
- NCT00410033
- Testing
- soluble human insulin, isophane human insulin, insulin aspart
- Where
- Sweden
- Volunteers
- 74 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications
The trial is designed as a feasibility study to determine the correlation of noninvasive measurements of AGE with the SCOUT device to diabetes complications.
- Trial name
- MARC (NCT01415115)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- VeraLight, Inc.
Diabetes, Diabetes Mellitus, Type 1
GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus
This study is conducted in Asia, Europe and in the United States of America. The aim of this study is to examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01950650
- Testing
- No treatment given, survey
- Where
- 10 sites in United States, China and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Novo Nordisk A/S
Diabetic Nephropathy
Effect of Pyridorin in Patients With Diabetic Nephropathy
The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.
- Trial name
- NCT00320021
- Testing
- Pyridorin (pyridoxamine dihydrochloride)
- Volunteers
- 80 people
- Sponsor
- BioStratum
Type 1 Diabetes
Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients
The purpose of this study is to determine if DiaPep277 can effectively protect the internal production of insulin in patients newly diagnosed with type 1 diabetes, by stopping the immune destruction of insulin-producing…
- Trial name
- DIA-AID (NCT00615264)
- Testing
- DiaPep277
- Where
- 34 sites in Austria, Czechia and 9 more
- Volunteers
- 457 people
- Sponsor
- Andromeda Biotech Ltd.
Diabetic Nephropathy
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria and Moderately Decreased GFR
- Trial name
- NCT01756716
- Testing
- MT-3995 Low, MT-3995 High
- Where
- 50 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 49 people
- Sponsor
- Tanabe Pharma Corporation
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects
Primary Objective: To assess the relative bioavailability of sotagliflozin following single doses of 3 sotagliflozin prototype tablet formulations p1, p2 and p3 versus the reference tablet formulation in fasted conditions in…
- Trial name
- NCT03310944
- Testing
- sotagliflozin (SAR439954)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type2 Diabetes, Type1diabetes
Accuracy Characterization Study
To demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring System (System) interstitial glucose results against venous glucose reference and capillary fingerstick using the Consensus Error Grid over the wear…
- Conditions
- Type2 Diabetes, Type1diabetes, Insulin Dependent Diabetes
- Trial name
- ACS (NCT01932944)
- Testing
- No treatment
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus, Type 1
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by injection under the skin.
- Trial name
- NCT03449433
- Testing
- LY900014, Insulin Lispro, Insulin Aspart
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Diabetes Type 1
ACZ885 in Type 1 Diabetes Mellitus
This study will assess the safety and efficacy of ACZ885 on stimulated C-peptide during a mixed meal test in patients with newly-diagnosed type 1 diabetes mellitus.
- Trial name
- NCT01322321
- Testing
- ACZ885
- Where
- 10 sites in United States, Canada and 2 more
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes Mellitus
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
This Phase 2 study was intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and efficacy of sotagliflozin following daily oral administration for 29 days in participants with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT01742208
- Testing
- Sotagliflozin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus
Pivotal Omnipod Horizon™ Automated Glucose Control System
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting and…
- Trial name
- NCT04196140
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 16 sites in United States
- Volunteers
- 240 people
- Sponsor
- Insulet Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.